



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/976,804	10/12/2001	Maximilian Polyak	053137-5001-01	2434

7590 03/15/2004

Kim R. Jessum
MORGAN, LEWIS & BOCKIUS LLP
1701 Market Street
Philadelphia, PA 19103

EXAMINER

SAUCIER, SANDRA E

ART UNIT	PAPER NUMBER
----------	--------------

1651

DATE MAILED: 03/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/976,804	Applicant(s) POLYAK ET AL.	
	Examiner Sandra Saucier	Art Unit 1651	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 January 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-27 is/are pending in the application.
- 4a) Of the above claim(s) 7,8,13-18 and 20-27 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-6,9-12 and 19 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>7/02, 10/01</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1651

DETAILED ACTION

Claims 1-27 are pending. Claims 1-6, 9-12, 19 are considered on the merits. Claims 7, 8, 13-18, 20-27 are withdrawn from consideration as being drawn to a non-elected invention.

Election/Restriction

Claims 7, 8, 13-18, 20-27 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected, the requirement having been traversed in Paper No. 1/5/04.

Applicant's election with traverse of Group I in Paper No. 1/5/04 is acknowledged. The traversal is on the ground that claims 7, 8 and 13-18 are species of claim 1. This is not found persuasive because composition A may not be restricted from compositions A+B, or from A+B+C, or from A+B+C+D as these form a tree of further limitations. However, compositions A+B and A+C and A+D, etc. are distinct compositions and may be properly restricted.

Applicants argue that serious burden has not been established. Serious burden is found in the search and prosecution of multiple inventions, especially with regard to the literature search.

Upon allowance of a product claim, method claims directed to the use and making of the allowable product may be rejoined. Please be aware that the method claims should properly depend from the composition claims which are deemed to be allowable and that applicant should amend the method claims to depend from the examined composition claims in order to preserve their right of rejoinder.

The requirement is still deemed proper and is therefore made FINAL.

Claim Rejections - 35 USC § 112

INDEFINITE

Art Unit: 1651

Claims 9-11 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The above claims use the abbreviation mcg/L for the concentration of prostaglandin. This does not appear to be an abbreviation commonly used in the art. Please provide evidence as to its meaning.

Claim Rejections – 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent, (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Fukuse *et al.* [U].

The claims are directed to a composition comprising:
prostaglandin (E1),
NO donor (nitroglycerin)
glutathione-forming agent (N-acetylcysteine).

The references are relied upon as explained below.

Fukuse *et al.* disclose a composition (ET-K) comprising :
prostaglandin E1, 25µg/kg
nitroglycerin,
N-acetylcysteine,
See Table 1 and page 1213.

Claim Rejections – 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1651

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-6, 9-12 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Polyak *et al.* [7] or Polyak *et al.* [3] in view of US 5,552,267 [IDS].

Polyak *et al.* [7] disclose a composition comprising Belzer II and 500µg/l prostaglandin E1 useful for perfusing kidney.

Polyak *et al.* [3] disclose a composition comprising Belzer MPS or Belzer II and 500µg/l prostaglandin E1 useful for perfusing kidney.

The references lack the inclusion of NAC and nitroglycerin.

US 5,552,267 discloses a perfusion solution for use with organs such as kidney (col. 10, l. 35) comprising a vasodilator in an amount sufficient to maintain vascular homeostasis, glucose, Mg⁺⁺, macromolecules, K⁺, and buffer (col. 4, l. 62). Further, the inclusion of NAC is preferred to the inclusion of glutathione (col. 3, l. 25) because it is more effective. The preferred concentration of NAC is 0.1-5mM (col. 16, l. 11) and of nitroglycerin is 0.05-0.2 g/l (col. 13, l. 40). The solution may be used to perfuse kidney (col. 10, l. 36).

The substitution of NAC for the glutathione in the composition of Belzer MPS or Belzer II would have been obvious when Polyak *et al.* (either reference) was taken with US 5,552,267 which teach the superiority of the use of NAC instead of glutathione in perfusion compositions (col. 3, l. 24-32).

Further, the inclusion of a vasodilator such as nitroglycerin in a solution for perfusion such as Belzer II or Belzer MPS would have been obvious when

Art Unit: 1651

taken with US 5,552,267 which teach the inclusion of vasodilators such as nitroglycerin in order to maintain homeostasis in perfusion solutions containing glucose, Mg^{++} , macromolecules, K^{+} , and buffer (col. 4, l. 63). Belzer II or Belzer MPS contain these ingredients and are used to perfuse organs such as kidney; thus, it would have been obvious to include a vasodilator in these solutions.

With regard to any differences that there may be in the concentration of the ingredients of the solution, in the absence of evidence to the contrary concerning the criticality of the concentration, this is considered to be an optimization of concentrations and is well within the purview of one of ordinary skill in the art.

All the components of the composition have been taught by the prior art to be useful in kidney perfusion solutions.

Claims 1-6, 9-12 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 5,712,084 [A] or US 5,200,398 [IDS] in view of US 5,552,267 [IDS] and Vargas *et al.* [V].

US 5,712,084 discloses the composition of the solution termed "Belzer MPS" (col. 6, l. 26-37) or UW (Belzer II) with a 5% HES concentration used for kidney perfusion.

US 5,200,398 teach that UW solution has glutathione, raffinose, potassium lactobionate, magnesium sulfate, phosphate buffer, hydroxyethyl starch, adenosine, allopurinol as components, Table I.

The primary referenced lack the inclusion of nitroglycerin, PGE1 and NAC in the standard UW type solutions used in the art.

Vargas *et al.* disclose the perfusion of kidney with a solution containing the vasodilator, prostaglandin E1. The total dosage administered was 35-37

Art Unit: 1651

mg/kg. The administration of prostaglandin E1 vasodilates the kidney and decreases renal injury that occurs after ischemia.

US 5,552,267 teaches the superiority of the use of NAC instead of glutathione in perfusion compositions (col. 3, l. 24-32) and the desirability of the inclusion of vasodilators. Specifically mentioned is nitroglycerin.

The inclusion of a vasodilator such as nitroglycerin or PGE1 in a solution for perfusion such as Belzer II or Belzer MPS would have been obvious when US 5,712,084 or US 5,200,398 was taken with US 5,552,267 which teach the inclusion of vasodilators such as nitroglycerin in order to maintain homeostasis in perfusion solutions containing glucose, Mg^{++} , macromolecules, K^+ , and buffer (col. 4, l. 63) and Vargas *et al.* who demonstrates the efficacy of PGE1 perfusion in kidney in a plain saline solution. Belzer II or Belzer MPS contain the ingredients taught in '267 and are used to perfuse organs such as kidney; thus, it would have been obvious to include vasodilators such as nitroglycerin and PGE1, which has been taught by Vargas *et al.* to be extremely useful for prevention of kidney damage in these kidney perfusion solutions.

The substitution of NAC for the glutathione in the composition of Belzer MPS or Belzer II which contains 5% HES 200-300KDa would have been obvious when US 5,712,084 was taken with US 5,552,267 which teach the superiority of the use of NAC instead of glutathione in perfusion compositions (col. 3, l. 24-32).

It is well known that it is prima facie obvious to combine two or more ingredients each of which is taught by the prior art to be useful for the same purpose in order to form a third composition which is useful for the same purpose. The idea for combining them flows logically from their having been used individually in the prior art. In re Pinten, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); In re Susi, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); In re Crockett, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

Art Unit: 1651

All the components of the solution are known in the art and have been used for kidney perfusion in the same concentrations. The results of the use of the solution appear to be the results which would be expected by one of ordinary skill in the art because NAC is clearly taught to be superior to glutathione and PGE1, a vasodilator, has been shown to be efficacious in preventing kidney damage in ischemia.

No claim is allowed.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1651. The supervisor for 1651 is M. Wityshyn. The normal work schedule for Examiner Saucier is 8:30 AM to 5:00 PM Monday and Tuesday and 8:30 AM to noon on Wednesday.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Saucier whose telephone number is (571) 272-0922. Status inquiries must be directed to the Customer Service Desk at (703) 308-0197 or (703)-308-0198. The number of the Fax Center for the faxing of official papers is (703) 872-9306.

A handwritten signature in black ink, appearing to read 'Sandra Saucier', with a stylized flourish at the end.

Sandra Saucier
Primary Examiner
Art Unit 1651
March 8, 2004